Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could olive juice compounds help shield the aging brain?

NCT ID NCT07672938

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 29, 2026 · Last updated Jul 01, 2026 · Updated 2 times

Summary

This study investigates whether a supplement made from hydroxytyrosol-rich olive juice, combined with a Mediterranean diet, can help prevent cognitive decline in people with mild cognitive impairment (MCI). Participants aged 50 to 85 with MCI will receive either a low or high dose of the supplement or a placebo, along with diet support, for 52 weeks. The goal is to see if this natural approach can slow memory and thinking problems.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Hydroxytyrosol-rich olive juice polyphenol supplement
What this could lead to
If it works, this could point toward a simple dietary approach to slow or prevent memory loss in people with early cognitive problems.
What could go wrong
This is a small, early-stage trial with 141 participants, so results may not apply to everyone. The supplement may show no benefit over placebo, and long-term effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 141 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * GR-based men and women aged 50 - 85 * Willingness and ability to conform to the full protocol. * Ability to accept and sign the consent form. * Presence of a diagnostic classification of Mild Cognitive Impairment according to the National Institute on Aging and Alzheimer's Association (NIA-AA) framework MCI, which corresponds to stage 3 on the pre-dementia range. * MoCA score of ≥18 and ≤ 26. Or * MMSE (Mini-Mental State Examination) score of ≥26 and ≤ 28. * No active suicide ideation based on the Columbia-Suicide Severity Rating Scale. * Absence of severe depressive symptomatology based on the Geriatric Depression Scale-15. * Not using any laxative drugs for at least three days prior to the screening visit. * Information about APOE status Exclusion Criteria: * Patients with mild, moderate, or severe dementia. * Current or recent (within the last 4 weeks) engagement with a strict dietary regime i.e., vegetarian / vegan / ketogenic / paleolithic / high protein / weight loss. * Any known issues with blood taking. * Any known bleeding disorders. * Any known allergy to olives, inability to tolerate gluten or multiple allergies/intolerances that would significantly limit food intake. * Average alcohol use of \>21 glasses per week for men and \>14 glasses per week for women (on average for the last six months). * History of psychiatric illness including intellectual disability, schizophrenia, bipolar disorder, severe, active depression and alcoholism. * Neurologic conditions such as vascular dementia, movement disorders, history of conditions such as anaemia and cancer in the last five years, renal or liver failure, malignant tumours, or organ transplant. * Coffee consumption greater than 5 cups per day. * Body mass index \> 35 kg/ m2. * Not taking a stable dose of statins for at least 3 months before the recruitment visit. Taking antibiotics in the 1 week preceding the recruitment visit. * Pregnancy or lactation. * Participation in another clinical trial during the last 30 days prior to the recruitment visit. * Subject taking supplements that may affect lipoprotein metabolism, \>1 g of fish oil/day, antioxidant supplements, cannabidiol (CBD) oil.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mild cognitive impairment (MCI) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cognitive Dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Palliative Care Centre "Panagia Glykofilousa", Greek Association of Alzheimer's Disease and Related Disorders, Plastira 65, Thessaloniki 54250, Greece.

    RECRUITING

    Thessaloniki, Central Macedonia, 54250, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.